HEMISPHERX BIOPHARMA (HEB) Looks To Run
The scientists identify Hemispherx Biopharma’s drug technology as the “most promising” mucosal adjuvant for influenza.
Hemispherx Biopharma (HEB): Ampligen (Poly I: Poly C12U) NDA (three month PDUFA decision date delay was announced on 2/18/09 as additional data was submitted by HEB within three months of original decision date). Ampligen is an experimental treatment for chronic fatigue syndrome (which has no FDA-approved treatments) and the drug has an Orphan Drug Status with a PDUFA decision date of 5/25/09 – 6/9/09.
So the announcement should be made any time between now and next Tuesday! I am speculating HEB will go to around 5.00 – 5.75, (There has been some questions coming in as to my price targets. I believe we could see the $5.00 range as the news leaks. With approval I would not rule out a DNDN like scenerio of $15-$20)but that is only my opinion based on my own DD. Also take a look at this FREE trend analysis information below. Just put in HEB your first name and e-mail and they send a report to your in-box!
Strong Uptrend
HEMISPHERX BIOPHARMA INC (AMEX:HEB)
Smart Scan Chart Analysis confirms a triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
FREE Trend analysis for HEB Here
3 Responses to “HEMISPHERX BIOPHARMA (HEB) Looks To Run”
Comment on this post below.
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
[...] Because Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies, many investors rush in to take shares of the newly listed companies. Interestingly, final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap indexes won’t become official until June 29, but that didn’t keep the excitement from continuing after hours for some investors with big block buys and volume on Hemispherx BioPharma, Inc. (AMEX:HEB) 2.85 +0.45 (18.75%) Courtesy of Biomedreports. Another article that shows HEB is for real Stockmarketnewz [...]
HAT’S OFF TO CARTER! THANKS FOR NOT GIVING UP IN YOUR QUEST TO MARKET AMPLIGEN! WHATEVER HAPPENS FROM HERE, I KNOW THAT YOU WILL DO YOUR BEST FOR THE PEOPLE IN THIS WORLD.
MY SCREEN NAME FOR MY FRIENDS ON THE BOARD………..CAJUNLADY!